Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Suzhou Highfine Biotech CoSZSE:301393 +9.21%89 OCF Margin % is 43.53% as of Mar. 2026, which is 102% above its 10-year median of 21.58. GuruFocus rates SZSE:301393 with a GF Score™ of 89/100 and a GF Value™ of ¥71.31 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 964 Drug Manufacturers companies, Suzhou Highfine Biotech Co ranks better than 81.43% on this metric.
The historical rank and industry rank for Suzhou Highfine Biotech Co's OCF Margin % or its related term are showing as below:
SZSE:301393'
s OCF Margin % Range Over the Past 10 Years
Min: 12.9 Med: 21.58 Max: 31.58
Current: 21.88
During the past 13 years, the highest OCF Margin % of Suzhou Highfine Biotech Co was 31.58%. The lowest was 12.90%. And the median was 21.58%.
SZSE:301393's OCF Margin % is ranked better than 81.43% of 964
companies
in the Drug Manufacturers industry
Industry Median: 10.025
vs SZSE:301393: 21.88
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Suzhou Highfine Biotech Co's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzhou Highfine Biotech Co OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Suzhou Highfine Biotech Co's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Suzhou Highfine Biotech Co's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzhou Highfine Biotech Co (SZSE:301393) has a OCF Margin % of 43.53% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Suzhou Highfine Biotech Co and its competitors. This is 102% above median its historical median of 21.58. Over the past decade, Suzhou Highfine Biotech Co's OCF Margin % has ranged from 12.90 to 31.58. According to the industry distribution chart, Suzhou Highfine Biotech Co ranks #179 out of 964 companies in the Drug Manufacturers industry, placing it in the top 18.6%.
Is Suzhou Highfine Biotech Co's OCF Margin % too high?
Suzhou Highfine Biotech Co's current OCF Margin % of 43.53% is 102% above median its 10-year median of 21.58. Over the past 10 years, this metric has ranged from a low of 12.90 to a high of 31.58. The Drug Manufacturers industry median OCF Margin % is 10.03. Suzhou Highfine Biotech Co's value of 43.53% is 334.2% above this industry median. Based on the distribution chart, Suzhou Highfine Biotech Co ranks #179 out of 964 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Suzhou Highfine Biotech Co has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzhou Highfine Biotech Co's OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Suzhou Highfine Biotech Co ranks #179 out of 964 companies for OCF Margin %. This places Suzhou Highfine Biotech Co in the top 19% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 10.03. Suzhou Highfine Biotech Co's value of 43.53% is 334.2% above this benchmark. Historically, Suzhou Highfine Biotech Co's own OCF Margin % has ranged from 12.90 to 31.58 over the past decade. While the company's 10-year median is 21.58 vs. the industry median of 10.03, Suzhou Highfine Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.03, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suzhou Highfine Biotech Co's current OCF Margin % of 43.53% is 334.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Suzhou Highfine Biotech Co and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Highfine Biotech Co's current OCF Margin % is 43.53%, which is 102% above median its own 10-year median of 21.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Highfine Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Highfine Biotech Co (SZSE:301393) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥71.31, compared to a current price of ¥56.11 — trading 21.3% below its estimated fair value. The current OCF Margin % is 43.53%, which is 102% above median its 10-year median of 21.58 and 334.2% above the Drug Manufacturers industry median of 10.03. Suzhou Highfine Biotech Co's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Suzhou Highfine Biotech Co (SZSE:301393), the current OCF Margin % is 43.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzhou Highfine Biotech Co (SZSE:301393) Overvalued in 2026?
Based on GuruFocus' analysis, Suzhou Highfine Biotech Co stock appears to be undervalued.
The current stock price of ¥56.11 is trading 21.3% below its estimated GF Value™ of ¥71.31.
GuruFocus considers Suzhou Highfine Biotech Co to be Modestly Undervalued.
Key valuation signals for SZSE:301393:
OCF Margin %: 43.53% (102% above median its 10-year median of 21.58)
GF Value™: ¥71.31 vs. price of ¥56.11 (21.3% below fair value)
Industry Position: 334.2% above the Drug Manufacturers median (#179 of 964)
No single metric tells the full story. See the SZSE:301393 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzhou Highfine Biotech Co Ltd is a high-tech enterprise that provides characteristic raw materials for global pharmaceutical research and development and raw material drug production companies. The products are mainly used in the fields of peptide, nucleotide and pharmaceutical synthesis. The product range covers peptide synthesis reagents for characteristic amide bond formation, molecular building blocks, protein reagents, liposome and lipid nanoparticle pharmaceutical reagents, ionic liquids , PROTAC reagents and nucleotide reagents and other types.
89GF Score
Get the complete analysis for SZSE:301393
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301393 has been successfully added to your 
